XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
LINES OF CREDIT
3 Months Ended
Mar. 31, 2021
LINES OF CREDIT  
NOTE 9 - LINES OF CREDIT

A summary of the Company’s lines of credit as of March 31, 2021 and December 31, 2020 is presented below:

 

 

 

March 31,

2021

 

 

December 31,

2020

 

National

 

$ 2,837,626

 

 

$ 3,540,550

 

Alpha

 

 

1,088,358

 

 

 

1,106,894

 

Pancretan

 

 

364,550

 

 

 

-

 

National - COVID

 

 

489,592

 

 

 

429,240

 

Total

 

$ 4,780,126

 

 

$ 5,076,684

 

       

The line of credit with National Bank of Greece is being renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2”) and 4.35% (plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit), (“COSME 1”). The maximum borrowing allowed for the 6% line of credit was $2,583,460 and $2,690,600 at March 31, 2021 and December 31, 2020, respectively for the 6% line of credit. The outstanding balance was $1,790,935 and $2,411,182 at March 31, 2021 and December 31, 2020, respectively.

 

The maximum borrowing allowed was $1,174,300 and $1,223,000 at March 31, 2021 and December 31, 2020, respectively, for the 4.35% lines of credit. The outstanding balance was $1,046,691 and $1,129,368 at March 31, 2021 and December 31, 2020, respectively.

 

The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,174,300 and $1,123,000 at March 31, 2021 and December 31, 2020, respectively. The outstanding balance was $1,088,358 and $1,106,894 at March 31, 2021 and December 31, 2020, respectively.

 

The Company entered into a line of credit with Pancreta bank on February 23,2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed was $587,150 at March 31, 2021. The outstanding balance was $364,550 at March 31, 2021.

 

Interest expense for the three months ended March 31, 2021 and 2020, was $16,501 and $17,673, respectively.

 

Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. During the three months ended March 31, 2021 and December 31, 2020, the Company was in compliance with these ratios and covenants.

 

COVID-19 Government Funding

 

On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to borrow a maximum of €500,000 ($611,500) under a proposed plan which will operate the same as the line of credit above. The proposed plan has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds were paid in 3 equal monthly installments. The line of credit is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 2.7%. The outstanding balance was $489,592 and $429,240 at March 31, 2021 and December 31, 2020.

 

Interest expense for the three months ended March 31, 2021 was $0.